RHHBY Licenses Simcere SIM0660 Tri-Specific in $1.53B Deal

Roche (OTC: RHHBY) licensed SIM0660, a preclinical tri-specific T-cell engager, from Simcere Zaiming for $75 million upfront and up to $1.53 billion in total milestone payments, plus tiered double-digit royalties. The antibody pairs two B-cell antigens, CD79a and CD19, with a CD3 arm that recruits T cells to kill those B cells.

The dual B-cell targeting is the point. Most B-cell drugs hit CD20 or CD19 alone, and patients can relapse when the target thins out or the cell switches antigen. Hitting CD79a and CD19 at once is designed to deepen depletion and reach patients who progressed on earlier B-cell therapies, in both blood cancers and autoimmune disease. The molecule is preclinical, and Simcere has not disclosed a lead indication or timeline.

T-cell engagers work by lashing a T cell to a target cell, forcing the immune system to kill it. The CD3 arm does the lashing; the CD79a and CD19 arms pick the target. Simcere says the design limits cytokine release, the inflammatory burst that has complicated other engagers, but that claim is untested in humans. The autoimmune angle is the bigger prize: B-cell depleters such as rituximab already anchor lupus and rheumatoid arthritis care, and a deeper depleter could reach patients who do not respond to anti-CD20 alone. Roche has not said which route it will pursue first.

RHHBY closed at $53.09 on September 1.

The headline number overstates the near-term economics. Only the $75 million upfront is guaranteed; the remaining roughly $1.46 billion is development, regulatory, and commercial milestones that may never be reached. That structure is standard: the seller banks a small upfront and trades the rest of the value for a shot at royalty income.

Roche already anchors the B-cell field with rituximab, obinutuzumab, and its CD20xCD3 bispecifics, so SIM0660 is an effort to stay ahead as that franchise faces patent pressure. The deal is Roche’s third Asia-sourced licensing pact in about a week, after a $190 million upfront for Hanmi’s clinical-stage UCN2 analog and a DualityBio antibody platform deal. The pattern suggests Genentech is buying, not building, B-cell and T-cell-engager depth after mixed results in its in-house immunology pipeline.

For Simcere Zaiming, a 2023-founded oncology subsidiary of Simcere Pharmaceutical Group (2096.HK), this is the sixth out-licensing deal, pushing its aggregate potential deal value past $6.1 billion. It is further evidence that China biotechs have become a reliable deal-flow source for Big Pharma.

What to watch: Roche’s choice of first indication, which will signal whether SIM0660 is aimed at oncology, autoimmunity, or both. Preclinical tri-specifics still face manufacturing and cytokine-release hurdles before any human data.